...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle‐invasive carcinoma of the bladder: Does histologic subtype matter?
【24h】

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle‐invasive carcinoma of the bladder: Does histologic subtype matter?

机译:辅助化疗对膀胱肌肉侵袭性癌患者患者的助剂化疗对膀胱切除术治疗膀胱切除术的影响:组织学亚型物质吗?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background The use of adjuvant chemotherapy (AC) in pure urothelial carcinoma of the bladder is established. Regarding variant histology, there is a gap in knowledge concerning the optimal treatment after radical cystectomy (RC). The objective of this study was to assess the effect of AC on overall survival (OS) in patients who had pure urothelial carcinoma, urothelial carcinoma with concomitant variant histology, or another pure variant histology. Methods Within the National Cancer Data Base, 15,397 patients who underwent RC for nonmetastatic, localized carcinoma of the bladder and had positive lymph nodes (T2N+) or locally advanced stage (≥T3N0/N+) were identified, excluding those who had previously received neoadjuvant chemotherapy. Multivariable Cox regression models were used to examine the specific effect of AC on OS stratified by each distinct histologic subtype, including pure urothelial carcinoma, micropapillary or sarcomatoid differentiation, squamous cell carcinoma, adenocarcinoma, and neuroendocrine tumors. To account for immortal time bias, Cox regression analyses and Kaplan‐Meier analyses were conducted with a landmark at 3 months. Results In multivariable landmark analyses, AC compared with initial observation was associated with an OS benefit for patients who had pure urothelial carcinoma (hazard ratio, 0.87; 95% confidence interval, 0.82‐0.91), whereas no differences were observed with regard to those who had variant histology. Conclusions Multivariable Cox regression landmark analysis revealed a survival benefit from AC for patients with a pure urothelial carcinoma. However, a survival benefit of AC for patients who had urothelial carcinoma with concomitant variant histology or other pure variant histology was not demonstrated.
机译:背景技术建立了助剂化疗(AC)在膀胱纯尿路上皮癌中的使用。关于变体组织学,有关于自由基膀胱切除术(RC)后的最佳治疗的知识存在差距。本研究的目的是评估AC对具有纯尿路上皮癌,尿路上皮癌的患者的整体存活(OS)的影响,包括伴随变体组织学,或其他纯变种组织学。国家癌症数据库内的方法,15,397名膀胱非更换,局部癌癌的患者进行阳性淋巴结(T2N +)或局部晚期阶段(≥T3N0/ n +),不包括先前接受Neoadjuvant化疗的人。使用多变量的Cox回归模型来检查每个不同组织学亚型分层的AC对OS的特异性效果,包括纯尿路上皮癌,微血小杂体或SarcomaToid分化,鳞状细胞癌,腺癌和神经内分泌肿瘤。要考虑不朽的时间偏见,COX回归分析和Kaplan-Meier分析在3个月内进行了标志性。结果在多变量的地标分析中,与初始观察相比,对具有纯尿癌癌的患者的OS益处有关(危险比,0.87; 95%置信区间,0.82-0.91),而对那些人没有观察到差异有变体组织学。结论多变量COX回归标志性分析显示纯尿路上皮癌的患者AC的生存益处。然而,没有证明具有伴随变体组织学或其他纯变体组织学的尿路上皮癌的患者的AC的存活效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号